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Abstract 
Human cells face many dangers, including chemicals, viruses and ionizing radiation. If cells 
are damaged in sensitive places by these attackers the effect can be disastrous. Highly 
regulated processes become deregulated due to genetic alterations that lead to cellular 
transformation. Guardians of genomes (Tumour suppressor genes) play a crucial role in the 
protection of our cells. Tumour suppressor genes are involved in a diversity of cellular 
processes such as cell cycle control, replication, recombination, signal transduction, repair, 
differentiation and aging. One of our guardian genes is p53 Tumour suppressor gene; restrict 
cell cycle progression, p53 lost its function by genetic alteration (mutation) or some external 
factors. TP53 gene contribute to about half of the cases of human cancer. Most of the 
mutations that cause mutant p53 protein production are missense mutations, mutant p53 
unable to stop multiplication in the damaged cell. The function of p53 protein can also be 
blocked by indirect factors.  Some viral proteins form complexes with p53 protein thereby 
functionally inactivating it, accumulation of wild type p53 in the cytoplasm, over expression 
of mdm2 protein are also inactivate p53 protein, PTEN mutation leads to an increase of AKT 
activity, an increase of nuclear mdm2 and impairs p53 response  
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1.INTRODUCTION 
 
       p53 is a tumor suppressor protein and which is encoded by TP53 gene located on the 
human chromosome17 (17p13.1). Like other tumor suppressor, the function of p53 to prevent 
unregulated cell growth, to maintain genomic stability and plays an important role in the 
protection of our body from cancer [1]. In normal cells, the level of p53 protein is kept low by 
the combination of another protein called mdm2. This protein binds to p53 preventing its 
action and transports it from the nucleus to the cytosol and degraded by proteasome under 
non-stressed conditions[15].The level of p53 proportionally increases in the response to 
genotoxic insults such as DNA damage, hypoxia activation, ionizing radiation, oncogene 
activities, some chemical agents, ribonucleotide depletion, and telomere shortening. Active 
p53 protein take a role as transcription factor and binds to several genes including 
WAF1/CIP1 to stimulate the transcription of p21 WAF1/CIP1 protein. p21 / WAF1 also 
known as cyclin-dependent kinase inhibitor1. p21 binds to CDK/cyclin complexes (molecules 
important for the G1/S transition  in the cell cycle) inhibiting their activity. This would allow 
time to repair the DNA. If repair is not possible, p53 stimulates the cell apoptosis 
(programmed cell death) [2]. In normal cells, regulation of cell division is done by these two 
proteins but in cancer cells the controls are no longer functioning properly. The mutation of 
the TP53 gene causes the genetic change and mostly seen in cancer cells. Approximately half 
of all cases of human cancer attributed to a mutant p53 protein. [2]. TP53 mutations can be 
within the p53 coding sequence and has a negative effect on the thermodynamic stability of 
the p53 protein.  Unlike most other tumour suppressor genes that are inactivated by frameshift 
or nonsense mutations, almost 90% of p53 gene mutations are missense mutations in which a 
single nucleotide is substituted by another. As a result of this, a stable mutant p53 protein is 
produced with a defective DNA binding domain and accumulating in the nucleus of tumor 
cells [19]. In addition to the loss of normal regulatory function of p53 protein that a mutation 
in TP53 may cause, many p53 mutants have positive effects on the development of tumor by 
several ways [4]. In a heterozygous situation ( both wild type (WT) and mutant alleles exist), 
expressing both wild-type and mutp53, mutant  p53 work against WTp53 tumor suppressor 
functions. The transcriptional activity of WT p53 is blocked by mutant p53[5].   Eventually, 
in the course of tumor progression, the remaining WT TP53 allele is often lost (mostly by 
deletion), further enhancing tumorigenesis. 
 
2.MAJOR FACTORS THAT INACTIVATE p53 REGULATION 
P53 protein plays a crucial role in the cell cycle of multicellular organisms, where it is 
involved in transactivation of a variety of growth-inhibitory signals of cell cycle control, via 
specific mechanisms. Its inactivation may lead to uncontrolled cell proliferation and a 
predisposition to abnormal proliferation. [10] 
There are several ways that inactivate p53. 
1. Mutational Inactivation 
 Inactivation of the p53 gene is essentially due to missense in which a single nucleotide is 
substituted by another which lead to either expression of a mutant protein (90% of cases) or 
absence of protein (10% of cases) In a high percentage of human tumors, p53 is always 
functionally impaired. ―The p53 mutational type differs among cancers of the colon, lung, 
esophagus, breast, liver, brain, reticuloendothelial tissues, and hemopoietic tissues. 
Transitions predominate in colon, brain, and lymphoid malignancies, whereas G:C to T:A 
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transversions are the most frequent substitutions observed in cancers of the lung and liver. 
Mutations at A:T base pairs are seen more frequently in esophageal carcinomas than in other 
solid tumors. Most transitions in colorectal carcinomas, brain tumors, leukemias, and 
lymphomas are at CpG dinucleotide mutational hot spots. G to T transversions in lung, breast, 
and esophageal carcinomas are dispersed among numerous codons". [20]  
 
 
Figure : p53.free.fr 
  
 
2.1.  Indirect (Mutation-independent) Inactivation of p53 
 
 Viral oncoproteins such as E6 protein (HPV), SV40 Large T antigen, E1B protein 
(adenoviruas), IE84 protein  (Human Cytomegalovirus)  binds with P53 protein, and 
functionally inactivating it as a result p53 proteins are degraded [9], [11]. Certain HPV types 
such as HPV type 16 and type 18 lead to infection of cervix. If not treated they can cause 
irreversible changes leading to cervical cancer. [6] 
 
2.2 Nuclear Exclusion of P53 
Molecular and immunohistochemical analyses indicate that wild type p53 accumulates in the 
cytoplasm, such as, in the case of Inflammatory breast carcinomas (37%)  and  95% of 
undifferentiated  neuroblastomas tumour  cells have these characteristics, this accumulation 
causes  functional inactivation of p53 [7] [8].  In some breast cancers the wild-type p53 
protein is accumulated in the cytoplasm and stabilized. The exclusion of the p53 protein from 
the cell nucleus inactivates the p53 function (unable to inhibit the cellular proliferation)[7]. 
Similar case is also observed in normal lactating breast tissue in which accumulation of p53 in 
the cytoplasm of ductal cells. This observation indicates that estrogen-mediated cell division 
could involve inactivation of p53 protein via exclusion from the cell nucleus. In this case, the 
cancer cells might use an altered version of a physiological mechanism to retain p53 in the 
cytoplasm. ―While the mechanism by which the wild-type p53 could be retained in the 
cytoplasm is not known, an interesting hypothesis derives from the fact that one of the nuclear 
localization signals is located between amino acid residues 316 and 321. Serine-315 can be 
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phosphorylated by a cdc2-like kinase. It is therefore possible that a growth-regulatory signal, 
such as an active cdc2-like kinase, could alter p53 protein via phosphorylation and exclude it 
from the nucleus‖ [7].  ―The cytoplasmic (wild-type) p53 group had the longest overall 
survival, with an average of 38 monthsfrom the time of diagnosis (45 months if one patient 
who died immediately after diagnosis is not included), whereas the nuclear (mutant) p53 
group had the shortest, with 20 months' survival. Although these data suggest that survival 
time and estrogen receptor status may correlate well with high levels of wild-type cytoplasmic 
p53 Protein‖[7].―Neuroblastoma cell lines with cytoplasmic p53 showed decreased cell cycle 
arrest response after DNA damaging treatments. This may result from p53 being excluded 
from the nuclear compartment, where it normally functions as a transcription factor. 
Therefore, exclusion of p53 from the nucleus may compromise the ability of p53 to exert its 
tumor suppressor function and may be an important alternative mechanism of p53 inactivation 
during tumor development‖. [8] 
  
2.3 Accumulation of mdm2 Protein 
―MDM2 gene (Murine Double Minute) encodes for a 90-kD protein that forms a complex 
with p53 protein and inhibits its transactivating properties‖. ―[10]  ―The MDM2protein is one 
key regulator of p53 activity. MDM2 inhibits p53 activity by two way. First, MDM2 binds to 
the N-terminal trans-activation domain (TAD) of p53, preventing transcription of downstream 
targets. Second, MDM2 functions as an E3 ubiquitin ligase to maintain low protein levels of 
p53 under non-stressed conditions and to return p53 to normal levels after a damage response 
is resolved‖[15]. ―Overexpression of MDM2 in tumor cells including leukemia and 
lymphomas is reported in several article , which allows its association with p53, is mainly due 
to MDM2 gene amplification, but other mechanisms have also been described, including an 
elevated level of MDM2 mRNA or enhanced levels of translation‖. [10]―Although these 
tumours would be expected to no longer express p53, the opposite situation is generally 
observed, with a large number of tumours overexpressing both p53 and mdm2. The reasons 
for this have not been clarified. No formal exclusion between p53 gene mutation and mdm2 
accumulation has been clearly demonstrated, suggesting that this situation could be due to an 
oncogenic activity of mdm2 independent of p53‖. [10], [11] 
 
2.4   PTEN Mutation 
―Phosphotase and tensin homolog (PTEN) is a protein that, in humans is encoded by the 
PTEN gene. Mutations of this gene cause development of many cancers. PTEN is a lipid 
phosphatase that negatively regulates the phosphatidylinositol 3-kinase (PI3K) signaling 
pathway‖[13]. ―PI3K–PTEN signaling pathway promotes cell survival and proliferation, 
increases in cell size and chemoresistance. Each of these biological outcomes results from the 
interaction of this pathway with other signalling networks‖. [13] 
     ―When PTEN is deleted, mutated or inactivated result in activation of PI3K effectors, 
particularly the activation of the key survival kinase protein kinase B (PKB, also known as 
AKT) can occur in the absence of any exogenous stimulus, and tumorigenesis can be 
initiated‖. [12,13]  
  
   ―AKT kinase phosphorylates mdm2 protein and induces its migration into the nucleus 
where it binds and ubiquinates p53. Upon growth factor activation, mdm2 activation through 
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AKT activation ensure proper cell growth. PTEN, a p53 regulated gene, down regulate the 
AKT pathway. PTEN deletion leads to an increase of AKT activity, an increase of nuclear 
mdm2 and impairs p53 response‖. [13] 
2.5   AKT Alteration 
―The p53 tumor suppressor protein and the Akt/PKB kinase play important roles in the 
transduction of pro-apoptotic and anti-apoptotic signals, respectively. Phosphorylation of 
Mdm2 by AKT enables its translocation from the cytoplasm into the nucleus, and the 
subsequent inactivation of nuclear p53 by Mdm2, mdm2 activation through AKT activation 
ensure proper cell growth‖.[14],[ 15] 
    ―Although no mutation of AKT has been found in human cancer, constitutive activation of 
its kinase activity has been observed via deregulation of the upstream pathway. An increase of 
AKT activity leads to an increase of nuclear mdm2 and incapacitates p53 and overcome its 
pro-apoptotic effects‖. [14] 
―Akt has been implicated in the down-regulation of p53 via MDM2. Studies have shown that 
MDM2 is phosphorylated by AKT at different sites, resulting in its stabilization Other studies 
have shown nuclear translocation of MDM2 in response to phosphorylation by AKT. This 
results in decreased p53 transcriptional activity from MDM2 binding at the transactivation 
domain and increases the ubiquitylation of p53‖. [ 15] 
 
2.5   AKT Alteration 
     ―Two major effectors of cell cycle checkpoint responses are ATM and ATR, protein 
kinases that phosphorylate cellular substrates in response to various forms of genetic stress. In 
response to DNA damage , p53 and mdm2 are phosporylated by two protein kinases the 
ataxia telangiectasia mutated (ATM) and ATR  serine/threonine kinases.  This causes 
dissociation of p53 from mdm2, leading to increased p53 protein levels and transcription of 
genes leading to cell cycle arrest (p21) or apoptosis‖. [16], [17] 
     ―One of the check point is G2 check point (during which the fidelity of DNA replication is 
assessed and errors are corrected. [17] The G2checkpoint system includes immediate and 
sustained signaling events to prevent cells from entering mitosis with damaged chromatids. 
Ataxia telangiectasia (AT) cells with inactivating mutations in ATM displays a defect in G2 
checkpoint function, inactivation of G2 checkpoint function thus may contribute to the genetic 
instability that characterizes cancer‖. 
     ―ATM is a high-molecular–weight protein kinase encoded at 11q22-23, ATM can 
associate with and phosphorylate p53 at serine 15 and is involved in the dephosphorylation of 
p53 at serine 376, both events are associated with p53 activation. Reduced levels of ATM 
protein have been detected in tumor cells from 30% to 40% of patients with Chronic 
Lymphocytic Leukomia‖. [18] 
  
3.DISCUSSION 
TP53 gene contribute to about half of the cases of human cancer, so that mutation in TP53 
gene may involve in the initiation of malignant transformation.  
   Other data in other tumour tissue also suggest that Mdm2 is playing important role in p53 
regulation. The results also indicate that MDM2 could be most important inhibitor of p53 
 322 
 
even when expressed at low levels. Therefore, MDM2 may play a broader role in the 
functional inactivation of p53 during tumor development.  
  
    Normal lactating breast tissue accumulates p53 in the cytoplasm of ductal cells and similar 
case seen in some breast cancers the wild-type p53 protein is accumulated in the cytoplasmic 
compartment of the cell and stabilized. Lactating breast tissue may have some protective 
mechanism against cancer.  
 
4.CONCLUSION 
    Tumor suppressor genes are involved in a diversity of cellular processes such as cell cycle 
control, replication, recombination, signal transduction, repair, differentiation and aging. One 
of our guardian gene is p53 Tumor suppressor gene, restrict cell cycle progression, Its control 
over the cells  division is lost with genetic alteration (mutation) or some external factors 
leading to its inactivation. 
    TP53 gene contribute to about half of the cases of human cancer. Most of these are 
missense mutations, changing the information in the DNA at one position and causing the cell 
to build p53 with an error, mutant p53 unable to stop multiplication in the damaged cell. 
   The function of p53 protein can also be blocked by indirect factors.  Some viral proteins 
form complexes with p53 protein thereby functionally inactivating it. Another inactivation 
factor, accumulation of wild type p53 in the cytoplasm. While the mechanism by which the 
wild-type p53 could be retained in the cytoplasm is not known,   37%of inflammatory breast 
carcinomas and 95% of undifferentiated neuroblastomas tumour cells have this type of 
inactivation.  Mdm2 is an important negative regulator of p53. Mdm2 protein functions both 
as an E3 ubiquitin ligase that recognizes N– terminal trans-activation domain (TAD) of the 
p53 and inhibitor of p53 transcriptional activity. Overexpression of MDM2 is observed in 
many tumours especially sarcomas, PTEN deletion leads to an increase of AKT activity, an 
increase of nuclear md 
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